Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection-Reference-Cited by-同舟云学术

Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection

Published:2022-03-08 Issue:5 Volume:111 Page:1155-1164
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Hullegie‐Peelen Daphne M.¹²,Zwan Marieke¹,Clahsen‐van Groningen Marian C.²³,Mustafa Dana A.M.³⁴,Baart Sara J.⁵,Reinders Marlies E.J.¹²,Baan Carla C.¹²,Hesselink Dennis A.¹²

Affiliation:

1. Department of Internal Medicine Division of Nephrology & Transplantation Erasmus MC Erasmus University Medical Center Rotterdam The Netherlands

2. Erasmus MC Transplant Institute Rotterdam The Netherlands

3. Department of Pathology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

4. The Tumor Immuno‐Pathology Laboratory Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

5. Department of Biostatistics Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2566

Reference50 articles.

1. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

2. Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation

3. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

4. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation;British Journal of Clinical Pharmacology;2024-07-26

2. Investigational drugs for the treatment of kidney transplant rejection;Expert Opinion on Investigational Drugs;2022-10-03

3. Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients;Pharmacogenomics;2022-07